D5 receptor Inhibitors
1 drugsAbout D5 receptor
The D5 receptor is a dopamine receptor subtype and G protein-coupled receptor (GPCR) in the central nervous system (CNS). It mediates intracellular signaling pathways in response to dopamine, a neurotransmitter involved in neurological processes.
The D5 receptor represents a potential drug target within the CNS, though research lags behind other dopamine receptors. Currently, there is no genetic evidence available linking the D5 receptor to specific diseases.
ONAPGO is the only FDA-approved drug targeting the D5 receptor, approved in 2025. It is a small molecule developed by MDD US for CNS indications.
Top D5 receptor Drugs
MDD US is the only company with an approved drug targeting the D5 receptor.
Low competition suggests a first-mover advantage, but also highlights potential challenges in market validation.
D5 receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets D5 receptor, using small molecule modality.
The absence of other modalities indicates a whitespace opportunity for novel biologics targeting the D5 receptor.
D5 receptor Clinical Trials 9 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on D5 receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 3 | 0 | 1 | 1 | 0% |
| Phase 3 | 2 | 2 | 0 | 0 | 100% |
| Phase 4 | 4 | 3 | 1 | 0 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
D5 receptor Drug Approval Timeline (2025 - 2025)
The first and only drug, ONAPGO, was approved in 2025.
Recent approval suggests renewed interest in the target, but it is too early to assess market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 8 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on D5 receptor. A trial counts if an approved drug acting on D5 receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.